Systemic Bioactivity of Inhaled Nebulized RNS60

Trial Profile

Systemic Bioactivity of Inhaled Nebulized RNS60

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2015

At a glance

  • Drugs RNS 60 (Primary)
  • Indications Alzheimer's disease; Asthma; Multiple sclerosis; Myocardial infarction; Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Revalesio
  • Most Recent Events

    • 16 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jul 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 09 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top